CN105330675A - Hiv复制的抑制剂 - Google Patents

Hiv复制的抑制剂 Download PDF

Info

Publication number
CN105330675A
CN105330675A CN201510602538.4A CN201510602538A CN105330675A CN 105330675 A CN105330675 A CN 105330675A CN 201510602538 A CN201510602538 A CN 201510602538A CN 105330675 A CN105330675 A CN 105330675A
Authority
CN
China
Prior art keywords
methyl
compound
pyridin
tetrahydrochysene
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510602538.4A
Other languages
English (en)
Chinese (zh)
Inventor
A.S.贝尔
I.B.加德纳
D.C.普里德
F.M.瓦肯胡特
K.R.吉布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK Ltd
Original Assignee
ViiV Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK Ltd filed Critical ViiV Healthcare UK Ltd
Publication of CN105330675A publication Critical patent/CN105330675A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201510602538.4A 2010-11-15 2011-11-01 Hiv复制的抑制剂 Pending CN105330675A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41361810P 2010-11-15 2010-11-15
US61/413618 2010-11-15
US201161485355P 2011-05-12 2011-05-12
US61/485355 2011-05-12
CN201180065030.5A CN103429595B (zh) 2010-11-15 2011-11-01 Hiv复制的抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180065030.5A Division CN103429595B (zh) 2010-11-15 2011-11-01 Hiv复制的抑制剂

Publications (1)

Publication Number Publication Date
CN105330675A true CN105330675A (zh) 2016-02-17

Family

ID=44999830

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510602538.4A Pending CN105330675A (zh) 2010-11-15 2011-11-01 Hiv复制的抑制剂
CN201180065030.5A Expired - Fee Related CN103429595B (zh) 2010-11-15 2011-11-01 Hiv复制的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180065030.5A Expired - Fee Related CN103429595B (zh) 2010-11-15 2011-11-01 Hiv复制的抑制剂

Country Status (15)

Country Link
US (3) US8809363B2 (cg-RX-API-DMAC10.html)
EP (1) EP2640729B1 (cg-RX-API-DMAC10.html)
JP (2) JP5902704B2 (cg-RX-API-DMAC10.html)
CN (2) CN105330675A (cg-RX-API-DMAC10.html)
AR (1) AR083870A1 (cg-RX-API-DMAC10.html)
AU (2) AU2011330850B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013011991A2 (cg-RX-API-DMAC10.html)
CA (1) CA2817896A1 (cg-RX-API-DMAC10.html)
CL (1) CL2013001338A1 (cg-RX-API-DMAC10.html)
MX (1) MX343274B (cg-RX-API-DMAC10.html)
RU (1) RU2564445C2 (cg-RX-API-DMAC10.html)
TW (1) TWI445709B (cg-RX-API-DMAC10.html)
UY (1) UY33729A (cg-RX-API-DMAC10.html)
WO (1) WO2012066442A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201303433B (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
CA2817896A1 (en) * 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
US9199959B2 (en) 2011-10-25 2015-12-01 Shionogi & Co., Ltd. HIV replication inhibitor
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Hiv複製抑制劑
JP2016516692A (ja) 2013-03-13 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヒト免疫不全ウイルス複製の阻害剤
JP2016512511A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヒト免疫不全ウイルス複製の阻害剤
US9655889B2 (en) 2013-03-13 2017-05-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970297A1 (en) 2013-03-14 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014159959A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
KR102345381B1 (ko) 2013-06-25 2021-12-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
WO2015123230A1 (en) 2014-02-12 2015-08-20 Bristol-Myers Squibb Company Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) 2014-02-18 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
ES2687322T3 (es) 2014-02-19 2018-10-24 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de inmunodeficiencia humana
JP6579549B2 (ja) 2014-05-16 2019-09-25 塩野義製薬株式会社 Hiv複製阻害作用を有する3環性複素環誘導体
MX393057B (es) 2014-10-24 2025-03-24 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas.
TWI676618B (zh) 2014-10-24 2019-11-11 美商必治妥美雅史谷比公司 三環化合物
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
US10806734B2 (en) 2015-05-08 2020-10-20 Katholieke Universiteit Leuven Functional cure of retroviral infection
AU2016271762B2 (en) 2015-05-29 2020-01-23 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
CN111018912A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种抗病毒药物关键中间体的合成和纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310488A1 (en) * 2000-08-09 2003-05-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
WO2010130842A1 (en) * 2009-05-15 2010-11-18 Katholieke Universiteit Leuven Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5489586A (en) * 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Hiv阻害剤
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
CA2469592C (en) 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7763641B2 (en) 2001-12-21 2010-07-27 Tibotec Pharmaceuticals Ltd. Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
ES2324231T3 (es) * 2004-12-17 2009-08-03 F. Hoffmann-La Roche Ag Derivados de tieno-piridina como intensificadores alostericos de gaba-b.
KR20100108337A (ko) * 2007-11-15 2010-10-06 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
RU2402531C2 (ru) * 2008-09-24 2010-10-27 Александр Леонидович Гинцбург Биологически активные вещества, подавляющие патогенные бактерии
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011076765A1 (en) 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Novel antiviral compounds
CA2817896A1 (en) * 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びhivを治療するための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310488A1 (en) * 2000-08-09 2003-05-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
WO2010130842A1 (en) * 2009-05-15 2010-11-18 Katholieke Universiteit Leuven Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERGEY V. RYABUKHIN,等: "Heterocyclic ortho-aminocarbonyl compounds in the Friedlander reaction promoted by chlorotrimethylsilane", 《HETEROCYCLES》 *

Also Published As

Publication number Publication date
RU2013121788A (ru) 2014-12-27
JP2013542247A (ja) 2013-11-21
CL2013001338A1 (es) 2014-03-28
AU2011330850B2 (en) 2016-01-28
CN103429595A (zh) 2013-12-04
AU2016202565A1 (en) 2016-05-19
TWI445709B (zh) 2014-07-21
US8809363B2 (en) 2014-08-19
RU2564445C2 (ru) 2015-10-10
EP2640729A1 (en) 2013-09-25
UY33729A (es) 2012-06-29
CN103429595B (zh) 2015-10-21
JP2016164163A (ja) 2016-09-08
BR112013011991A2 (pt) 2016-08-30
MX2013005486A (es) 2013-12-12
JP5902704B2 (ja) 2016-04-13
TW201300395A (zh) 2013-01-01
AU2011330850A1 (en) 2013-06-27
US20120136023A1 (en) 2012-05-31
ZA201303433B (en) 2014-12-23
US20160355528A1 (en) 2016-12-08
WO2012066442A1 (en) 2012-05-24
AR083870A1 (es) 2013-03-27
US9447116B2 (en) 2016-09-20
US20140315927A1 (en) 2014-10-23
CA2817896A1 (en) 2012-05-24
MX343274B (es) 2016-10-31
EP2640729B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
CN103429595B (zh) Hiv复制的抑制剂
ES3025032T3 (en) Carboxy-benzimidazole glp-1r modulating compounds
JP5372751B2 (ja) Aza−ペプチドプロテアーゼ阻害剤
CN102770181B (zh) 抗病毒化合物
ES2574831T3 (es) Inhibidores de la proteasa antivirales
US20190375726A1 (en) Compounds for the treatment of hiv
CN108558871A (zh) 作为抗癌剂的新颖三环化合物
CN110511209A (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN105164142B (zh) 用于治疗细菌感染的甘露糖衍生物
TWI815887B (zh) 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
WO2021107066A1 (ja) インテグラーゼ阻害剤及び抗hiv薬を組み合わせることを特徴とするhiv感染症の予防及び治療用医薬
CN115916341A (zh) 用于治疗hbv的吡唑甲酰胺化合物
AU2013267072A1 (en) Aza-peptide protease inhibitors
HK40009971A (en) 1,3-thiazol-2-yl substituted benzamides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160217